NO20083236L - Trombinreseptorantagonister som profilakse mot komplikasjoner fra cardiopulmonar kirurgi - Google Patents

Trombinreseptorantagonister som profilakse mot komplikasjoner fra cardiopulmonar kirurgi

Info

Publication number
NO20083236L
NO20083236L NO20083236A NO20083236A NO20083236L NO 20083236 L NO20083236 L NO 20083236L NO 20083236 A NO20083236 A NO 20083236A NO 20083236 A NO20083236 A NO 20083236A NO 20083236 L NO20083236 L NO 20083236L
Authority
NO
Norway
Prior art keywords
thrombin receptor
receptor antagonists
prophylaxis against
cardiopulmonary surgery
against complications
Prior art date
Application number
NO20083236A
Other languages
English (en)
Inventor
Enrico P Veltri
John T Strony
Gail Berman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083236(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20083236L publication Critical patent/NO20083236L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Beskrevet her er metoder for forhindring, inhibering eller lindring av komplikasjoner assosiert med kardiopulmonal bypass-kirurgi ved anvendelse av en trombin-reseptorantagonistforbindelse. Blant trombinreseptorantagonistforbindelsene som er anvendbare i disse metoder, er de av formlene (I), (II) og (III) beskrevet her. Eksempler på slike trombinreseptor-antagonister innbefatter formlene (I), (II) og (III) .
NO20083236A 2005-12-22 2008-07-21 Trombinreseptorantagonister som profilakse mot komplikasjoner fra cardiopulmonar kirurgi NO20083236L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75324605P 2005-12-22 2005-12-22
PCT/US2006/048928 WO2007075964A2 (en) 2005-12-22 2006-12-20 Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery

Publications (1)

Publication Number Publication Date
NO20083236L true NO20083236L (no) 2008-09-22

Family

ID=38218643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083236A NO20083236L (no) 2005-12-22 2008-07-21 Trombinreseptorantagonister som profilakse mot komplikasjoner fra cardiopulmonar kirurgi

Country Status (11)

Country Link
US (2) US20070202140A1 (no)
EP (1) EP1971336A2 (no)
JP (1) JP2009521472A (no)
CN (1) CN101384259A (no)
AU (1) AU2006331583A1 (no)
BR (1) BRPI0620641A2 (no)
CA (1) CA2634216A1 (no)
NO (1) NO20083236L (no)
TW (1) TW200744593A (no)
WO (1) WO2007075964A2 (no)
ZA (1) ZA200806067B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
WO2009088063A1 (ja) * 2008-01-11 2009-07-16 Eisai R & D Management Co., Ltd. 医薬組成物、医薬組成物製造のための２－イミノピロリジン誘導体の使用および心疾患の治療用または改善用キット
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
WO2010057066A1 (en) * 2008-11-17 2010-05-20 Schering Corporation Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist
EP2434894B1 (en) * 2009-05-29 2016-08-31 Novartis AG Methods of administration of thrombopoietin agonist compounds
SI2438060T1 (sl) 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
EP2440191A2 (en) 2009-06-08 2012-04-18 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3024550A4 (en) 2013-07-22 2016-12-07 Merck Sharp & Dohme CO-CRYSTAL FROM THE PAR-1 RECEPTOR ANTAGONIST VORAPAXAR AND ASPIRIN
EP3340994A1 (en) * 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
WO2020101627A1 (en) * 2018-11-14 2020-05-22 Canakkale Onsekiz Mart Universitesi Rektorlugu A solution developed to be applied to the saphenous vein graft
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000A (en) * 1841-03-12 Improvement in the manufacture of starch
US3020A (en) * 1843-03-30 Improvement in disengaging horses from carriages
US4000A (en) * 1845-04-16 Combined lock and latch
US4019A (en) * 1845-05-01 Pianoforte
US4017A (en) * 1845-05-01 Reid r
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US4015A (en) * 1845-04-26 Hand-loom for weaving figured fabrics
US4568545A (en) * 1982-10-02 1986-02-04 Amano Seiyaku Kabushiki Kaisha Thrombolytic agent
TW499412B (en) * 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6613573B1 (en) * 1999-02-22 2003-09-02 Haemoscope Corporation Method and apparatus for monitoring anti-platelet agents
US6630451B1 (en) * 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US6515023B2 (en) * 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
KR100604742B1 (ko) * 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
EP1425015A4 (en) * 2001-08-20 2004-12-15 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS ANTITHROMBOTIC AGENTS
CA2463628A1 (en) * 2001-10-18 2003-04-24 Schering Corporation Himbacine analogues as thrombin receptor antagonists
EP1982984B1 (en) * 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
EP1721610B1 (en) * 2004-03-04 2009-05-13 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
DK1848705T3 (da) * 2005-01-14 2010-06-14 Schering Corp EXO- og diastereoselektive synteser af himbacin-analoger
US20070238674A1 (en) * 2006-04-06 2007-10-11 Veltri Enrico P Tra combination therapies

Also Published As

Publication number Publication date
CN101384259A (zh) 2009-03-11
BRPI0620641A2 (pt) 2011-11-16
WO2007075964A3 (en) 2007-09-20
WO2007075964A8 (en) 2007-12-13
JP2009521472A (ja) 2009-06-04
WO2007075964A2 (en) 2007-07-05
CA2634216A1 (en) 2007-07-05
AU2006331583A1 (en) 2007-07-05
ZA200806067B (en) 2009-08-26
US20090062239A1 (en) 2009-03-05
EP1971336A2 (en) 2008-09-24
US20070202140A1 (en) 2007-08-30
TW200744593A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
WO2007075964A3 (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
NO20090628L (no) Pyridizinon derivativater
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
WO2006134317A8 (en) Oxadiazole derivatives as dgat inhibitors
WO2007027532A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
DE602005023333D1 (de) Kinaseinhibitoren
WO2007034282A3 (en) Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
DK1869019T3 (da) Bicycliske [3.1.0]heteroarylamider som glycintransportinhibitorer type I
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
NO20080831L (no) 1,4-dihydropyridin-fuserte heterosykler, fremgangsmate for fremstilling av det samme, anvendelse og sammensetninger inneholdende dem
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
CR10722A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
UA101963C2 (en) 4-amino-pyrimidine derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application